reports
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
- Anthony Dick
- Michael Foundoukidis
- Thomas Zlowodzki
- Anthony Dick
- Michael Foundoukidis
- Thomas Zlowodzki
- Fehmi Ben Naamane
- Johanna Jourdain
- Fehmi Ben Naamane
- Johanna Jourdain
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain ...
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam ...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, ...
Angi Launches New “AI Helper” as it Celebrates 30 Years of Innovation
Angi Launches New “AI Helper” as it Celebrates 30 Years of Innovation DENVER, June 17, 2025 (GLOBE NEWSWIRE) -- Today, Angi—formerly known as Angie’s List—is introducing a new, “AI Helper” to its service request experience, as part of its continued effort to simplify how homeowners connect with top-quality service pros and meet demand for smarter, more intuitive home improvement solutions. This innovation coincides with Angi’s 30th anniversary, marking three decades of connecting homeowners with skilled pros and driving industry innovation. At the heart of this enhancement is an intellig...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness M...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of this year’s theme, “Your Path to Better Days,” Axsome is supporting more than a dozen events across the U.S. throughout the month of June and beyond. Axsome i...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multip...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the ...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) ...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not su...
Axsome Therapeutics Inc: 2 directors
Two Directors at Axsome Therapeutics Inc sold after exercising options/sold 48,173 shares at between 104.065USD and 104.450USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June: William Blair 45th Annual Growth Stock ConferenceThe Company will present on Tuesday, June 3, 2025, at 10:40 a.m. CT in Chicago, IL Jefferies Global Healthcare ConferenceThe Company will present on Thursday, June 5, 2025, at 2:35 p.m. ET in New ...
Axsome Therapeutics Presents Data from Three of Its Innovative Neurosc...
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations from three of its innovative neuroscience programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting, being held from May 27-30 in Scottsdale, Arizona. Details of the present...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation w...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey...
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit...
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (“Blackstone”). Concurrent with this new facility, Axsome has retired its previous term loan w...
Angi to Participate in the 53nd Annual J.P. Morgan Global Technology, ...
Angi to Participate in the 53nd Annual J.P. Morgan Global Technology, Media and Communications Conference DENVER, May 08, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) will participate in the 53nd Annual J.P. Morgan Global Technology, Media and Communications Conference on Thursday, May 15, 2025. CEO Jeffrey Kip will present at 8:40 a.m. ET. Both a live audio webcast and replay of the presentation will be available to the public in the IR section of Angi’s website at . About Angi Inc. Angi (NASDAQ: ANGI) helps homeowners get home projects done well and helps home service pros grow ...
Angi Inc. Earnings Release and Letter to Shareholders Available on Com...
Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its first quarter financial results and a letter to shareholders from CEO Jeffrey Kip on the investor relations section of its website at . As announced previously, Angi Inc. will host a conference call to discuss the company’s first quarter results and to answer questions. The call will be held on Wednesday, May 7, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate. The live audiocast and replay will...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.